Natco Pharma
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology. With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Natco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Natco Pharma's score of 32 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Natco Pharma's reported carbon emissions
In 2024, Natco Pharma reported total carbon emissions of approximately 60,268,600 kg CO2e, comprising 28,403,250 kg CO2e from Scope 1 and 41,763,620 kg CO2e from Scope 2 emissions. The company has also disclosed Scope 3 emissions, which totalled about 60,268,600 kg CO2e, primarily from purchased goods and services. In 2023, Natco Pharma's emissions were approximately 68,760,000 kg CO2e, with Scope 1 emissions at 20,898,100 kg CO2e and Scope 2 emissions at 39,945,230 kg CO2e. The company has shown a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been detailed in the available data. Overall, Natco Pharma's emissions reflect its operational scale, with a revenue of approximately USD 480 million in 2024. The company continues to monitor and report its emissions, aligning with industry standards for transparency and accountability in climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 13,265,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,696,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Natco Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
